AH-001
Undisclosed (likely oncology or neurodegeneration)
Phase 1Active
Key Facts
Indication
Undisclosed (likely oncology or neurodegeneration)
Phase
Phase 1
Status
Active
Company
About AnHorn Medicines
AI‑driven protein degradation company developing BIGPRO® therapeutics for cancer, neurodegeneration and aging.
View full company profile